Takeda Pharmaceutical Company Limited (TYO:4502)
Japan
· Delayed Price · Currency is JPY 4,288.00
+120.00 (2.88%)
Apr 18, 2025, 3:30 PM JST
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.14T JPY in the quarter ending December 31, 2024, with 2.96% growth. This brings the company's revenue in the last twelve months to 4.58T, up 9.83% year-over-year. In the fiscal year ending March 31, 2024, Takeda Pharmaceutical Company had annual revenue of 4.26T with 5.87% growth.
Revenue (ttm)
4,579.02B
Revenue Growth
+9.83%
P/S Ratio
1.43
Revenue / Employee
92.92M
Employees
49,281
Market Cap
6,532.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | 3,291.19B | 1,193.96B | 56.93% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,170.61B |
| Daiichi Sankyo Company | 1,795.99B |
| HOYA Corporation | 838.60B |
| Terumo | 1,011.15B |
| Otsuka Holdings | 2,329.86B |
| Astellas Pharma | 1,867.63B |
| Olympus | 993.33B |
| Shionogi & | 456.87B |
Takeda Pharmaceutical Company News
- 11 days ago - BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 - Accesswire
- 17 days ago - Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns - Seeking Alpha
- 5 weeks ago - Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
- 6 weeks ago - Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer - Benzinga
- 6 weeks ago - Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera - Business Wire
- 7 weeks ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - Benzinga
- 7 weeks ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 2 months ago - Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued - Seeking Alpha